Second primary malignancies in multiple myeloma: an overview and IMWG consensus
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Second primary malignancies in multiple myeloma: an overview and IMWG consensus
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume -, Issue -, Pages mdw606
Publisher
Oxford University Press (OUP)
Online
2016-11-04
DOI
10.1093/annonc/mdw606
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program
- (2016) Xin Du et al. BMC CANCER
- Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial
- (2016) Cyrille Hulin et al. JOURNAL OF CLINICAL ONCOLOGY
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
- (2016) Sagar Lonial et al. LANCET
- Connect MM® – the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide
- (2016) Robert M. Rifkin et al. LEUKEMIA & LYMPHOMA
- Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide
- (2016) Dana E. Rollison et al. LEUKEMIA & LYMPHOMA
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- New Cancers after Autotransplantations for Multiple Myeloma
- (2015) Anuj Mahindra et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma
- (2015) A. K. Stewart et al. BLOOD
- Multiple myeloma as a second primary malignancy; one fourth of patients had prior history of other malignances
- (2015) N. Nishimura et al. Clinical Lymphoma Myeloma & Leukemia
- Analysis of Second Primary Malignancies (SPMs) in CALGB (Alliance)/ECOG/BMT CTN 100104
- (2015) S.A. Holstein et al. Clinical Lymphoma Myeloma & Leukemia
- Guidelines for the correct determination of second primary malignancies in myeloma trials
- (2015) J. Jones et al. Clinical Lymphoma Myeloma & Leukemia
- Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
- (2015) Naveen Pemmaraju et al. Clinical Lymphoma Myeloma & Leukemia
- Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years
- (2015) M. Engelhardt et al. HAEMATOLOGICA
- Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study
- (2015) Gudbjörg Jonsdottir et al. HAEMATOLOGICA
- Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review
- (2015) Yucai Wang et al. JNCI-Journal of the National Cancer Institute
- Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial
- (2015) Francesca Gay et al. LANCET ONCOLOGY
- The risk of secondary primary malignancies after therapy for multiple myeloma
- (2015) Nuchanan Areethamsirikul et al. LEUKEMIA & LYMPHOMA
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
- (2015) Henk M. Lokhorst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years
- (2015) M. Engelhardt et al. HAEMATOLOGICA
- Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study
- (2015) Gudbjörg Jonsdottir et al. HAEMATOLOGICA
- Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review
- (2015) Yucai Wang et al. JNCI-Journal of the National Cancer Institute
- Second Primary Malignancies and Myeloma Therapy: Fad or Fact?
- (2015) Saad Z Usmani Oncotarget
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
- (2014) P. G. Richardson et al. BLOOD
- Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
- (2014) S. Bringhen et al. BLOOD
- Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
- (2014) Y. X. Zhu et al. BLOOD
- Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma
- (2014) P. Sonneveld et al. BLOOD
- Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival
- (2014) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
- (2014) Jesús F San-Miguel et al. LANCET ONCOLOGY
- Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data
- (2014) Antonio Palumbo et al. LANCET ONCOLOGY
- Lenalidomide and second malignancies in myeloma patients
- (2014) Guy Pratt LANCET ONCOLOGY
- Update on second primary malignancies in multiple myeloma: a focused review
- (2014) O Landgren et al. LEUKEMIA
- Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma
- (2014) S Z Usmani et al. LEUKEMIA
- Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations
- (2014) S Matarraz et al. LEUKEMIA
- Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents
- (2014) Morie A. Gertz et al. LEUKEMIA & LYMPHOMA
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
- (2014) Lotfi Benboubker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
- (2014) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups
- (2014) S Ailawadhi et al. Blood Cancer Journal
- BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma
- (2013) A. Rossi et al. BLOOD
- Multiple Myeloma and Second Malignancies
- (2013) Monika Engelhardt et al. Clinical Lymphoma Myeloma & Leukemia
- Multiple Myeloma and Other Malignancies: A Pilot Study From the Houston VA
- (2013) Reinhold Munker et al. Clinical Lymphoma Myeloma & Leukemia
- Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
- (2013) D. Siegel et al. HAEMATOLOGICA
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
- (2013) Jesus San Miguel et al. LANCET ONCOLOGY
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
- (2013) S K Kumar et al. LEUKEMIA
- Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma
- (2013) G Srivastava et al. LEUKEMIA
- Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients
- (2013) L E Roeker et al. LEUKEMIA
- Inherited genetic susceptibility to multiple myeloma
- (2013) G J Morgan et al. LEUKEMIA
- Time Trend of Multiple Myeloma and Associated Secondary Primary Malignancies in Asian Patients: A Taiwan Population–Based Study
- (2013) Huey-En Tzeng et al. PLoS One
- Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics
- (2013) P Razavi et al. Blood Cancer Journal
- Myeloid Neoplasms Secondary to Plasma Cell Myeloma: An Intrinsic Predisposition or Therapy-Related Phenomenon?
- (2012) Deepti M. Reddi et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Second malignancies after multiple myeloma: from 1960s to 2010s
- (2012) A. Thomas et al. BLOOD
- A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide
- (2012) M. A. Dimopoulos et al. BLOOD
- Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance
- (2012) S. Z. Usmani et al. BLOOD
- Multiple myeloma and its therapies: to what extent do they contribute to the increased incidence of second malignant neoplasms?
- (2012) Constantin A. Dasanu et al. CURRENT MEDICAL RESEARCH AND OPINION
- Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma
- (2012) Jesús F. San Miguel et al. JOURNAL OF CLINICAL ONCOLOGY
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
- (2012) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- MTHFR polymorphism and the risk of prostate cancer: a meta-analysis of case–control studies
- (2012) X-L Li et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)
- (2011) S. Mailankody et al. BLOOD
- The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study
- (2011) Danny R Youlden et al. BMC CANCER
- Secondary primary malignancies in patients with multiple myeloma treated with high-dose chemotherapy and autologous blood stem cell transplantation
- (2011) Roland Fenk et al. BRITISH JOURNAL OF HAEMATOLOGY
- Observations of Second Primary Malignancy in Patients With Multiple Myeloma
- (2011) Anne Ormerod et al. Clinical Lymphoma Myeloma & Leukemia
- Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma
- (2011) O Landgren et al. LEUKEMIA
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improvement in Survival of Older Adults with Multiple Myeloma: Results of an Updated Period Analysis of SEER Data
- (2011) D. Pulte et al. ONCOLOGIST
- Immune alterations in untreated and treated multiple myeloma
- (2011) Constantin A Dasanu JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma
- (2010) Jens Hasskarl et al. LEUKEMIA & LYMPHOMA
- A genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility
- (2009) J. A. Knight et al. BLOOD
- Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based Study
- (2009) Ingemar Turesson et al. JOURNAL OF CLINICAL ONCOLOGY
- MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility
- (2008) N. A. Ellis et al. BLOOD
- The role of MTHFR gene in multiple myeloma
- (2008) Elias Zintzaras et al. JOURNAL OF HUMAN GENETICS
- Familial Myeloma
- (2008) Henry T. Lynch et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started